Jim Cramer - Mad Money Karuna Therapeutics KRTX-Q BUY Aug 17, 2022

They have been working on a drug for schizophrenia. Early this month they released phase 3 trail results--which were great. Shares jumped 72% and keep climbing.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$261.160

Stock price when the opinion was issued

Pharma & Healthcare

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

COMMENT

An early-stage biopharma, so you can't buy their drugs right now, but they are developing drugs. Their lead drug treats schizophrenia as well as psychosis. Shares are up 21% YTD, but has pulled back hard in the past month.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jim Cramer - Mad Money Karuna Therapeutics KRTX-Q BUY Aug 17, 2022

You might be interested:

Karuna Therapeutics(KRTX-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights